Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis

P Kellokumpu-Lehtinen; H Joensuu; T Joensuu; P Hervonen; T Nyandoto; T Luukkaala; T Hemminki; R Asola; M Lukkaa; I Lehtinen

Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis

P Kellokumpu-Lehtinen, H Joensuu, T Joensuu, P Hervonen, T Nyandoto, T Luukkaala, T Hemminki, R Asola, M Lukkaa, I Lehtinen

Research output: Contribution to journal › Article › Scientific

Original language	English
Journal	EUR J CANCER
Volume	5
Issue number	suppl 285
Publication status	Published - 2007
Publication type	B1 Journal article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Kellokumpu-Lehtinen, P., Joensuu, H., Joensuu, T., Hervonen, P., Nyandoto, T., Luukkaala, T., Hemminki, T., Asola, R., Lukkaa, M., & Lehtinen, I. (2007). Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis. EUR J CANCER, 5(suppl 285).

@article{58800307f2a948d4a3bd79c73ad1e652,

title = "Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis",

author = "P Kellokumpu-Lehtinen and H Joensuu and T Joensuu and P Hervonen and T Nyandoto and T Luukkaala and T Hemminki and R Asola and M Lukkaa and I Lehtinen",

year = "2007",

language = "English",

volume = "5",

number = "suppl 285",

}

Kellokumpu-Lehtinen, P, Joensuu, H, Joensuu, T, Hervonen, P, Nyandoto, T, Luukkaala, T, Hemminki, T, Asola, R, Lukkaa, M & Lehtinen, I 2007, 'Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis', EUR J CANCER, vol. 5, no. suppl 285.

Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis. / Kellokumpu-Lehtinen, P; Joensuu, H; Joensuu, T et al.
In: EUR J CANCER, Vol. 5, No. suppl 285, 2007.

Research output: Contribution to journal › Article › Scientific

TY - JOUR

T1 - Phase III randomized open-label study of triweekly docetaxet (tT) vs. Biweekly docetaxel (dT) as treatment for advanced hormone refractory prostate cancer (HRPC): results from an iterim safety analysis

AU - Kellokumpu-Lehtinen, P

AU - Joensuu, H

AU - Joensuu, T

AU - Hervonen, P

AU - Nyandoto, T

AU - Luukkaala, T

AU - Hemminki, T

AU - Asola, R

AU - Lukkaa, M

AU - Lehtinen, I

PY - 2007

Y1 - 2007

M3 - Article

SN - 0959-8049

VL - 5

JO - EUR J CANCER

JF - EUR J CANCER

IS - suppl 285

ER -